{"pmid":32404189,"title":"The role of passive immunization in the age of SARS-CoV-2: an update.","text":["The role of passive immunization in the age of SARS-CoV-2: an update.","The rapid spread of the corona virus pandemic is an existential problem for many people in numerous countries. So far, there is no effective vaccine protection or proven therapy available against the SARS-CoV-2 virus. In this review, we describe the role of passive immunization in times of the corona virus. Passive immunization could be a bridging technology to improve the immune defense of critically ill patients until better approaches with effective medications are available.","Eur J Med Res","Fischer, Johannes C","Zanker, Kurt","van Griensven, Martijn","Schneider, Marion","Kindgen-Milles, Detlef","Knoefel, Wolfram Trudo","Lichtenberg, Artur","Tamaskovics, Balint","Djiepmo-Njanang, Freddy Joel","Budach, Wilfried","Corradini, Stefanie","Ganswindt, Ute","Haussinger, Dieter","Feldt, Torsten","Schelzig, Hubert","Bojar, Hans","Peiper, Matthias","Bolke, Edwin","Haussmann, Jan","Matuschek, Christiane","32404189"],"abstract":["The rapid spread of the corona virus pandemic is an existential problem for many people in numerous countries. So far, there is no effective vaccine protection or proven therapy available against the SARS-CoV-2 virus. In this review, we describe the role of passive immunization in times of the corona virus. Passive immunization could be a bridging technology to improve the immune defense of critically ill patients until better approaches with effective medications are available."],"journal":"Eur J Med Res","authors":["Fischer, Johannes C","Zanker, Kurt","van Griensven, Martijn","Schneider, Marion","Kindgen-Milles, Detlef","Knoefel, Wolfram Trudo","Lichtenberg, Artur","Tamaskovics, Balint","Djiepmo-Njanang, Freddy Joel","Budach, Wilfried","Corradini, Stefanie","Ganswindt, Ute","Haussinger, Dieter","Feldt, Torsten","Schelzig, Hubert","Bojar, Hans","Peiper, Matthias","Bolke, Edwin","Haussmann, Jan","Matuschek, Christiane"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32404189","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1186/s40001-020-00414-5","keywords":["bridge therapy","convalescent plasma","covid-19","high risk","immunology","intensive care unit","respiratory failure"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666802845368713217,"score":9.490897,"similar":[{"pmid":32420691,"title":"Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.","text":["Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.","Passive immunity against pathogens in epidemics has historical roots. Convalescent plasma (CP), plasma collected from individuals who have recovered from an infectious disease, has been used to confer therapeutic benefits in previous epidemics, including measles, mumps, and influenza, and remains the first line passive immunotherapy in emerging diseases, including the H1N1 influenza pandemic (2009) and now Covid-19 (1). Over the last several decades, as technology has developed to purify and manufacture plasma-derived immunoglobulin (IG) as a drug therapy, hyperimmune globulin (H-IG) formulations have been used as the second line of passive immunotherapies against these diseases.","Clin Transl Sci","Morabito, Christopher J","Gangadharan, Bagirath","32420691"],"abstract":["Passive immunity against pathogens in epidemics has historical roots. Convalescent plasma (CP), plasma collected from individuals who have recovered from an infectious disease, has been used to confer therapeutic benefits in previous epidemics, including measles, mumps, and influenza, and remains the first line passive immunotherapy in emerging diseases, including the H1N1 influenza pandemic (2009) and now Covid-19 (1). Over the last several decades, as technology has developed to purify and manufacture plasma-derived immunoglobulin (IG) as a drug therapy, hyperimmune globulin (H-IG) formulations have been used as the second line of passive immunotherapies against these diseases."],"journal":"Clin Transl Sci","authors":["Morabito, Christopher J","Gangadharan, Bagirath"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420691","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/cts.12816","topics":["Treatment"],"weight":1,"_version_":1667159284535787520,"score":149.42528},{"pmid":32310190,"title":"Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19.","text":["Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19.","The ongoing COVID-19 pandemic has infected nearly 400,000 individuals with 17000 deaths since it was first identified in human populations in December 2019, in Wuhan, China. No antiviral therapies or vaccines are available for their treatment or prevention. Passive immunization PI through broadly neutralizing antibodies that bind to the specific antigens of SARS-CoV 2 might be a potential solution to address the immediate health threat of COVID-19 pandemic while vaccines are being developed. The PI approach in treating COVID-19 is discussed herein, including a summary of its historical applications to confront epidemics.","Int J Risk Saf Med","Alzoughool, Foad","Alanagreh, Lo'ai","32310190"],"abstract":["The ongoing COVID-19 pandemic has infected nearly 400,000 individuals with 17000 deaths since it was first identified in human populations in December 2019, in Wuhan, China. No antiviral therapies or vaccines are available for their treatment or prevention. Passive immunization PI through broadly neutralizing antibodies that bind to the specific antigens of SARS-CoV 2 might be a potential solution to address the immediate health threat of COVID-19 pandemic while vaccines are being developed. The PI approach in treating COVID-19 is discussed herein, including a summary of its historical applications to confront epidemics."],"journal":"Int J Risk Saf Med","authors":["Alzoughool, Foad","Alanagreh, Lo'ai"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32310190","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.3233/JRS-201017","keywords":["covid-19","convalescent plasma","coronaviruses","passive immunization"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138491138867201,"score":141.14122},{"pmid":32407543,"title":"Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID -19 infected patients.","text":["Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID -19 infected patients.","COVID-19 pandemic is an emerging new human disease, where no vaccines, or monoclonal antibodies (mAbs), or drugs are currently available for therapy. Active vaccination requires the induction of an immune response against a given agent to a susceptible individual for the purpose of preventing or treating an infectious disease and this usually takes time to develop. Thus, the use of existing autologous Ab administration, obtainable from recovered COVID 19 patients, after 2 weeks recovery, is the best and the most practical strategy for providing immediate passive immunity to susceptible recipients in need.","Br J Haematol","Lanza, F","Seghatchian, J","32407543"],"abstract":["COVID-19 pandemic is an emerging new human disease, where no vaccines, or monoclonal antibodies (mAbs), or drugs are currently available for therapy. Active vaccination requires the induction of an immune response against a given agent to a susceptible individual for the purpose of preventing or treating an infectious disease and this usually takes time to develop. Thus, the use of existing autologous Ab administration, obtainable from recovered COVID 19 patients, after 2 weeks recovery, is the best and the most practical strategy for providing immediate passive immunity to susceptible recipients in need."],"journal":"Br J Haematol","authors":["Lanza, F","Seghatchian, J"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32407543","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/bjh.16814","topics":["Treatment"],"weight":1,"_version_":1666802845408559105,"score":132.1453},{"pmid":32467561,"pmcid":"PMC7255975","title":"Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.","text":["Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.","To date, no vaccines or effective drugs have been approved to prevent or treat COVID-19 and the current standard care relies on supportive treatments. Therefore, based on the fast and global spread of the virus, urgent investigations are warranted in order to develop preventive and therapeutic drugs. In this regard, treatments addressing the immunopathology of SARS-CoV-2 infection have become a major focus. Notably, while a rapid and well-coordinated immune response represents the first line of defense against viral infection, excessive inflammatory innate response and impaired adaptive host immune defense may lead to tissue damage both at the site of virus entry and at systemic level. Several studies highlight relevant changes occurring both in innate and adaptive immune system in COVID-19 patients. In particular, the massive cytokine and chemokine release, the so-called \"cytokine storm\", clearly reflects a widespread uncontrolled dysregulation of the host immune defense. Although the prospective of counteracting cytokine storm is compelling, a major limitation relies on the limited understanding of the immune signaling pathways triggered by SARS-CoV-2 infection. The identification of signaling pathways altered during viral infections may help to unravel the most relevant molecular cascades implicated in biological processes mediating viral infections and to unveil key molecular players that may be targeted. Thus, given the key role of the immune system in COVID-19, a deeper understanding of the mechanism behind the immune dysregulation might give us clues for the clinical management of the severe cases and for preventing the transition from mild to severe stages.","Signal Transduct Target Ther","Catanzaro, Michele","Fagiani, Francesca","Racchi, Marco","Corsini, Emanuela","Govoni, Stefano","Lanni, Cristina","32467561"],"abstract":["To date, no vaccines or effective drugs have been approved to prevent or treat COVID-19 and the current standard care relies on supportive treatments. Therefore, based on the fast and global spread of the virus, urgent investigations are warranted in order to develop preventive and therapeutic drugs. In this regard, treatments addressing the immunopathology of SARS-CoV-2 infection have become a major focus. Notably, while a rapid and well-coordinated immune response represents the first line of defense against viral infection, excessive inflammatory innate response and impaired adaptive host immune defense may lead to tissue damage both at the site of virus entry and at systemic level. Several studies highlight relevant changes occurring both in innate and adaptive immune system in COVID-19 patients. In particular, the massive cytokine and chemokine release, the so-called \"cytokine storm\", clearly reflects a widespread uncontrolled dysregulation of the host immune defense. Although the prospective of counteracting cytokine storm is compelling, a major limitation relies on the limited understanding of the immune signaling pathways triggered by SARS-CoV-2 infection. The identification of signaling pathways altered during viral infections may help to unravel the most relevant molecular cascades implicated in biological processes mediating viral infections and to unveil key molecular players that may be targeted. Thus, given the key role of the immune system in COVID-19, a deeper understanding of the mechanism behind the immune dysregulation might give us clues for the clinical management of the severe cases and for preventing the transition from mild to severe stages."],"journal":"Signal Transduct Target Ther","authors":["Catanzaro, Michele","Fagiani, Francesca","Racchi, Marco","Corsini, Emanuela","Govoni, Stefano","Lanni, Cristina"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32467561","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1038/s41392-020-0191-1","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668420887132504065,"score":118.48513},{"pmid":32348636,"title":"Hyposalivation as a potential risk for SARS-CoV-2 infection: Inhibitory role of saliva.","text":["Hyposalivation as a potential risk for SARS-CoV-2 infection: Inhibitory role of saliva.","Human saliva is an inquisitively complex fluid and has an imperative role for prevention and protection from viral infection, particularly through innate immune system, which is a prominent first-line defense against viral infection (Malamud et al., 2011; Dawes et al., 2015). Despite the clear role of saliva in the continuous cleansing of oral cavity, we focus on proteins that illustrate antiviral activity, particularly against corona viruses.","Oral Dis","Farshidfar, Nima","Hamedani, Shahram","32348636"],"abstract":["Human saliva is an inquisitively complex fluid and has an imperative role for prevention and protection from viral infection, particularly through innate immune system, which is a prominent first-line defense against viral infection (Malamud et al., 2011; Dawes et al., 2015). Despite the clear role of saliva in the continuous cleansing of oral cavity, we focus on proteins that illustrate antiviral activity, particularly against corona viruses."],"journal":"Oral Dis","authors":["Farshidfar, Nima","Hamedani, Shahram"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348636","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/odi.13375","topics":["Mechanism"],"weight":1,"_version_":1666138495447465984,"score":113.9744}]}